NYSE:NUVB Nuvation Bio (NUVB) Stock Price, News & Analysis $4.22 -0.13 (-2.99%) Closing price 11/10/2026 03:59 PM EasternExtended Trading$4.25 +0.03 (+0.71%) As of 06:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Nuvation Bio Stock (NYSE:NUVB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuvation Bio alerts:Sign Up Key Stats Today's Range$4.11▼$4.3650-Day Range$4.16▼$6.9352-Week Range$3.97▼$9.75Volume3.48 million shsAverage Volume5.36 million shsMarket Capitalization$1.48 billionP/E RatioN/ADividend YieldN/APrice Target$12.89Consensus RatingModerate Buy Company Overview Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer. The company conducts clinical development internationally and markets Ibtrozi in the United States. Its research and development activities include advancing potential treatments for cancers with substantial unmet medical needs.AI Generated. May Contain Errors. Read More Nuvation Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreNUVB MarketRank™: 2.96140165986 of 5 starsNuvation Bio scored higher than 59% of companies evaluated by MarketBeat, and ranked 358th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingNuvation Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 9 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialNuvation Bio has a consensus price target of $12.89, representing about 205.4% upside from its current price of $4.22.Amount of Analyst CoverageNuvation Bio has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nuvation Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nuvation Bio are expected to grow in the coming year, from ($0.36) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvation Bio is -10.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvation Bio is -10.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvation Bio has a P/B Ratio of 6.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.26% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvation Bio has recently decreased by 1.93%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvation Bio does not currently pay a dividend.Dividend GrowthNuvation Bio does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.02 News SentimentNuvation Bio has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Nuvation Bio this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for NUVB on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat Follows4 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nuvation Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $709,000.00 in company stock.Percentage Held by Insiders30.11% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvation Bio's insider trading history. Receive NUVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NUVB Stock News HeadlinesNuvation Bio (NUVB) Stock Trades Below Fair Value After Its 211% RunNovember 10 at 7:30 PM | finance.yahoo.comNuvation Bio to Present at the Jefferies Global Healthcare Conference in LondonNovember 10 at 4:05 PM | prnewswire.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 11 at 1:00 AM | Paradigm Press (Ad)Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks PatientsNovember 9 at 2:39 PM | seekingalpha.comNuvation Bio FY2026 Earnings Forecast Cut by HC WainwrightNovember 9 at 1:15 AM | americanbankingnews.comNuvation Bio (NYSE:NUVB) Sets New 1-Year Low After Analyst DowngradeNovember 8 at 1:21 AM | americanbankingnews.comNuvation Bio (NUVB) Gets a Buy from H.C. WainwrightNovember 6, 2026 | theglobeandmail.comB. Riley Adjusts Nuvation Bio Price Target to $13 From $14, Maintains Buy RatingNovember 5, 2026 | marketscreener.comMSee More Headlines NUVB Stock Analysis - Frequently Asked Questions How have NUVB shares performed this year? Nuvation Bio's stock was trading at $8.96 on January 1st, 2026. Since then, NUVB shares have decreased by 52.9% and is now trading at $4.22. How were Nuvation Bio's earnings last quarter? Nuvation Bio Inc. (NYSE:NUVB) issued its earnings results on Wednesday, November, 4th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.00. The firm earned $44.95 million during the quarter, compared to analysts' expectations of $34.39 million. Nuvation Bio had a negative trailing twelve-month return on equity of 45.69% and a negative net margin of 67.38%. Read the conference call transcript. Who are Nuvation Bio's major shareholders? Top institutional investors of Nuvation Bio include ACT Capital Partners L.P. (0.17%), Alps Advisors Inc. (0.13%), Russell Investments Group Ltd. (0.10%) and Torray Investment Partners LLC (0.08%). Insiders that own company stock include David Hung, Xiangmin Cui, Robert Mashal, Kim D Blickenstaff, Gary Hattersley, Kerry Wentworth, Stacy Markel, Dongfang Liu and Philippe Sauvage. View institutional ownership trends. How do I buy shares of Nuvation Bio? Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvation Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvation Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), IonQ (IONQ), Plug Power (PLUG), Tesla (TSLA) and Archer Aviation (ACHR). Company Calendar Last Earnings11/04/2026Today11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, NUVB's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:NUVB CIK1811063 Webwww.nuvationbio.com Phone332-208-6102FaxN/AEmployees310Year Founded2018Price Target and Rating Average Price Target for Nuvation Bio$12.89 High Price Target$21.00 Low Price Target$7.00 Potential Upside/Downside+205.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$204.63 million Net Margins-67.38% Pretax Margin-67.38% Return on Equity-45.69% Return on Assets-18.54% Debt Debt-to-Equity Ratio1.23 Current Ratio7.45 Quick Ratio7.30 Sales & Book Value Annual Sales$62.90 million Price / Sales23.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book6.49Miscellaneous Outstanding Shares351,120,000Free Float245,400,000Market Cap$1.48 billion OptionableOptionable Beta1.73 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NYSE:NUVB) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is Available to ClaimJames Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
